Engineered nano-bacteria hybrids for precision cancer immunotherapy
Source abstract
Abstract
Bacterial therapy has emerged as a promising modality in precision cancer immunotherapy, leveraging bacteria's innate tumor-homing ability, immunostimulatory properties, and engineering flexibility to overcome limitations in conventional treatments. This review highlights recent advances in integrating nanotechnology with bacterial systems to develop multifunctional platforms for precision cancer immunotherapy. We first discuss the development of nano-bacteria hybrids, including physical, chemical, and biological interface strategies for constructing multifunctional hybrids, as well as the therapeutic utility of bacterial-derived components such as outer membrane vesicles (OMVs), bacterial ghosts (BGs), and gas vesicles (GVs). We then discuss the synergistic integration of nano-bacteria hybrids with immune checkpoint blockade, CAR-T cell therapy, and genetic engineering approaches to enhance drug delivery, modulate the tumor microenvironment (TME), and improve immune activation. Finally, we explore innovative strategies to overcome current limitations in bacterial immunotherapy, such as tumor heterogeneity, immunosuppression, and safety concerns, while proposing future directions for the clinical translation of nano-bacteria hybrids.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Cancer Research and Treatments · Nanoplatforms for cancer theranostics · Bacteriophages and microbial interactions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Therapeutic cancer vaccines: advancements, challenges, and prospects10.1038/s41392-023-01674-3 ↗
2. Therapy with oncolytic viruses: progress and challenges10.1038/s41571-022-00719-w ↗
3. Exploring the next generation of antibody-drug conjugates10.1038/s41571-023-00850-2 ↗
4. Next-generation combination approaches for immune checkpoint therapy10.1038/s41590-024-02015-4 ↗
5. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas
6. Exploring the emerging role of the microbiome in cancer immunotherapy10.1186/s40425-019-0574-4 ↗
7. Bacteria and tumor: understanding the roles of bacteria in tumor genesis and immunology10.1016/j.micres.2022.127082 ↗
8. Clostridia in cancer therapy10.1038/nrmicro777 ↗
9. Bacteria in cancer initiation, promotion and progression10.1038/s41568-023-00594-2 ↗
10. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma10.1200/JCO.2002.20.1.142 ↗
11. Bacteria-cancer interactions: bacteria-based cancer therapy10.1038/s12276-019-0297-0 ↗
12. Nanotechnology for immuno-oncology10.1038/s43018-025-01025-x ↗
13. Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy10.1126/scitranslmed.abn1128 ↗
14. Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy
15. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy10.1038/nmat3355 ↗
16. Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy10.1038/s41467-021-21497-6 ↗
17. Enhancing cancer immunotherapy: Nanotechnology-mediated immunotherapy overcoming immunosuppression10.1016/j.apsb.2024.05.032 ↗
18. Synergistic brilliance: engineered bacteria and nanomedicine unite in cancer therapy
19. Nano/genetically engineered cells for immunotherapy10.1002/bmm2.12112 ↗
20. Bacterial nanotechnology as a paradigm in targeted cancer therapeutic delivery and immunotherapy10.1038/s41378-024-00743-z ↗
21. Bacterial therapies at the interface of synthetic biology and nanomedicine10.1038/s44222-023-00119-4 ↗
22. Optimizing cancer treatments to induce an acute immune response: radiation Abscopal effects, PAMPs, and DAMPs10.1158/1078-0432.CCR-12-1175 ↗
23. Immune suppression and reversal of the suppressive tumor microenvironment10.1093/intimm/dxy042 ↗
24. Live-attenuated Listeria-based immunotherapy10.1586/erv.13.34 ↗
25. Tissue CD14(+)CD8(+) T cells reprogrammed by myeloid cells and modulated by LPS10.1038/s41586-022-05645-6 ↗
26. Enterococcus peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy10.1126/science.abc9113 ↗
27. Role of lipoteichoic acid in infection and inflammation10.1016/S1473-3099(02)00226-8 ↗
28. Flagella of tumor-targeting bacteria trigger local hemorrhage to reprogram tumor-associated macrophages for improved antitumor therapy10.1002/adma.202303357 ↗
29. Engineering the perfect (bacterial) cancer therapy10.1038/nrc2934 ↗
30. Nanomedicine hitchhiking on bacteria for treating tumors
31. Harnessing bacterial agents to modulate the tumor microenvironment and enhance cancer immunotherapy10.3390/cancers16223810 ↗
32. Engineering nanoparticles for cancer immunotherapy: current achievements, key considerations and future perspectives10.1016/j.cej.2024.150356 ↗
33. Cancer nanovaccines: nanomaterials and clinical perspectives10.1002/smll.202401631 ↗
34. Bacteria and bacterial derivatives as delivery carriers for immunotherapy10.1016/j.addr.2021.114085 ↗
35. Advances of bacteria-based delivery systems for modulating tumor microenvironment10.1016/j.addr.2022.114444 ↗
36. The rational engineered bacteria based biohybrid living System for tumor therapy10.1002/adhm.202401538 ↗
37. Decorated bacteria and the application in drug delivery10.1016/j.addr.2022.114443 ↗
38. Bacteria and cancer: different sides of the same coin10.1016/j.lfs.2020.117398 ↗
39. Surface engineering on bacteria for tumor immunotherapy: strategies and perspectives10.1002/adfm.202405304 ↗
40. Generating self-adjuvated nanofiber vaccines by coating bacterial flagella with antigens10.1002/adma.202415887 ↗
41. Programmable bacteria‐based biohybrids as living biotherapeutics for enhanced cancer Sonodynamic‐Immunotherapy
42. Conjugated polymer-coated bacteria for multimodal intracellular and extracellular anticancer activity10.1002/adma.201204550 ↗
43. Dressing bacteria with a hybrid immunoactive nanosurface to elicit dual anticancer and antiviral immunity
44. Upconversion nanoparticles and its based photodynamic therapy for antibacterial applications: a state-of-the-art review10.3389/fchem.2022.996264 ↗
45. Aptamer-assisted tumor localization of bacteria for enhanced biotherapy10.1038/s41467-021-26956-8 ↗
46. Integrating bacteria with a ternary combination of photosensitizers for monochromatic irradiation-mediated photoacoustic imaging-guided synergistic photothermal therapy10.1021/acsnano.3c00032 ↗
47. Spatiotemporal delivery of dual nanobodies by engineered probiotics to reverse tumor immunosuppression via targeting tumor-derived exosomes10.1021/acsnano.4c08117 ↗
48. Harnessing the engineered probiotic-nanosystem to remodulate tumor extracellular matrix and regulate tumor-colonizing bacteria for improving pancreatic cancer chemo-immunotherapy
49. An oral bacterial pyroptosis amplifier against malignant Colon cancer10.1016/j.nantod.2023.102091 ↗
50. Aptamer-drug conjugates-loaded bacteria for pancreatic cancer synergistic therapy10.1038/s41392-024-01973-3 ↗
51. Multimodal oncolytic bacteria by coating with tumor cell derived nanoshells10.1016/j.nantod.2022.101537 ↗
52. Streptavidin-biotin technology: improvements and innovations in chemical and biological applications10.1007/s00253-013-5232-z ↗
53. Drug-loaded Bacillus calmette-guerin bacteria for immuno-chemo combo therapy in bladder cancer
54. Composition and functions of bacterial membrane vesicles10.1038/s41579-023-00875-5 ↗
55. Bacterial outer membrane vesicles suppress tumor by interferon-gamma-mediated antitumor response10.1038/s41467-017-00729-8 ↗
56. Bacteria-derived nanovesicles enhance tumour vaccination by trained immunity10.1038/s41565-023-01553-6 ↗
57. Engineered bacterial outer membrane vesicles as controllable two-way adaptors to activate macrophage phagocytosis for improved tumor immunotherapy10.1002/adma.202206200 ↗
58. Surface mineralization of engineered bacterial outer membrane vesicles to enhance tumor photothermal/immunotherapy10.1021/acsnano.3c05714 ↗
59. Dynamics of PhiX174 protein E-mediated lysis of Escherichia coli10.1007/BF00248685 ↗
60. Biochemical characterization of phi X174-protein-E-mediated lysis of Escherichia coli10.1111/j.1432-1033.1989.tb14661.x ↗
61. Bacterial ghosts as adjuvant particles10.1586/14760584.6.2.241 ↗
62. The bacterial ghost platform system: production and applications10.4161/bbug.1.5.12540 ↗
63. Cancer cell membrane-coated bacterial ghosts for highly efficient paclitaxel delivery against metastatic lung cancer10.1016/j.apsb.2023.08.012 ↗
64. Bacterial navigation for tumor targeting and photothermally-triggered bacterial ghost transformation for spatiotemporal drug release10.1016/j.actbio.2021.06.030 ↗
65. Design and immune characterization of a novel Neisseria gonorrhoeae DNA vaccine using bacterial ghosts as vector and adjuvant10.1016/j.vaccine.2018.06.006 ↗
66. Gas vesicles, microbiol
67. Biogenic gas nanostructures as ultrasonic molecular reporters10.1038/nnano.2014.32 ↗
68. Acoustic reporter genes for noninvasive imaging of microorganisms in Mammalian hosts10.1038/nature25021 ↗
69. Modification of PEG reduces the immunogenicity of biosynthetic gas vesicles
70. Ultrasound molecular imaging of epithelial mesenchymal transition for evaluating tumor metastatic potential via targeted biosynthetic gas vesicles10.1002/smll.202207940 ↗
71. Magneto-acoustic protein nanostructures for non-invasive imaging of tissue mechanics in vivo10.1038/s41563-023-01688-w ↗
72. Engineered outer membrane vesicles as nanosized immune cell engagers for enhanced solid tumor immunotherapy10.1021/acsnano.4c07364 ↗
73. Self-Blockade of PD-L1 with bacteria-derived outer-membrane vesicle for enhanced cancer immunotherapy10.1002/adma.202106307 ↗
74. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
75. Nanodrug-bacteria conjugates-mediated oncogenic collagen depletion enhances immune checkpoint blockade therapy against pancreatic cancer
76. Applications of synthetic biology in medical and pharmaceutical fields10.1038/s41392-023-01440-5 ↗
77. Tweak to treat: reprograming bacteria for cancer treatment10.1016/j.trecan.2020.11.004 ↗
78. Engineered oncolytic bacteria for malignant solid tumor treatment10.1002/INMD.20240005 ↗
79. Ultrasound-controllable engineered bacteria for cancer immunotherapy10.1038/s41467-022-29065-2 ↗
80. Reprogramming a doxycycline-inducible gene switch System for bacteria-mediated cancer therapy10.1007/s11307-023-01879-6 ↗
81. Genetic programming by nitric oxide-sensing gene switch System in tumor-targeting bacteria10.3390/bios13020266 ↗
82. Enhancing the tropism of bacteria via genetically programmed biosensors10.1038/s41551-021-00772-3 ↗
83. Synchronized cycles of bacterial lysis for in vivo delivery10.1038/nature18930 ↗
84. Engineered Lactococcus lactis secreting Flt3L and OX40 ligand for in situ vaccination-based cancer immunotherapy10.1038/s41467-022-35130-7 ↗
85. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice10.1158/0008-5472.CAN-06-0716 ↗
86. Tal danino 1 3 4, engineering bacteria as interactive cancer therapies10.1126/science.add9667 ↗
87. RGD peptide cell-surface display enhances the targeting and therapeutic efficacy of attenuated salmonella-mediated cancer therapy10.7150/thno.16135 ↗
88. RGD-Expressed bacterial membrane-derived nanovesicles enhance cancer therapy via multiple tumorous targeting10.7150/thno.51988 ↗
89. Engineered attenuated Salmonella typhimurium expressing neoantigen has anticancer effects10.1021/acssynbio.1c00097 ↗
90. Probiotic neoantigen delivery vectors for precision cancer immunotherapy10.1038/s41586-024-08033-4 ↗
91. Biosynthetic neoantigen displayed on bacteria derived vesicles elicit systemic antitumour immunity10.1002/jev2.12289 ↗
92. Programmable bacteria induce durable tumor regression and systemic antitumor immunity10.1038/s41591-019-0498-z ↗
93. A programmable oral bacterial hydrogel for controllable production and release of nanovaccine for tumor immunotherapy10.1016/j.biomaterials.2023.122147 ↗
94. Metabolic challenges and interventions in CAR T cell therapy
95. Advancements and challenges in CAR T cell therapy in autoimmune diseases10.1038/s41584-024-01139-z ↗
96. CAR-T cell therapy: the efficacy and toxicity balance, curr. Hematol. Malig
97. Nanotechnology‐based CAR‐T strategies for improving efficacy and safety of tumor immunotherapy
98. Nanomaterials boost CAR-T therapy for solid tumors10.1002/adhm.202304615 ↗
99. Efficient non-viral CAR-T cell generation via silicon-nanotube-mediated transfection10.1016/j.mattod.2023.02.009 ↗
100. Inhibition of post-surgery tumour recurrence via a hydrogel releasing CAR-T cells and anti-PDL1-conjugated platelets10.1038/s41551-021-00712-1 ↗